View Alert
Versions:


Originator: CMO Messaging

From: CMO Messaging

Issue date: Originally issued on 01-Feb-2021 12:22:59. This version was issued on 01-Feb-2021 12:22:59

This alert has been issued to:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • Special Health Authorities
  • NHS Trusts (England) - Medical Director
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Regional Directors of Public Health
  • Consultants in Communicable Diseases
  • CMO Urgent Messages - Recipients on Public Health Link
  • Director of Public Health
  • NHS Trusts (England) - Chief Executive

Action category: Action

Title: Interleukin-6 inhibitors (tocilizumab and sarilumab) for critically ill patients with COVID-19 pneumonia (adults)

Broadcast content: NHS trusts / health boards are recommended to consider prescribing either tocilizumab or sarilumab to hospitalised patients with COVID-19 pneumonia being treated with non-invasive ventilation (including high-flow nasal oxygen therapy or continuous positive airway pressure ventilation) or invasive mechanical ventilation.


Please note: we have updated the alert pdf to correct the link to the Medusa monograph.


Additional information: This alert is not relevant to Primary Care.

Alert reference: CEM/CMO/2021/004

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency